Loading organizations...
Loading organizations...
Nabriva Therapeutics is a biopharmaceutical company developing and commercializing novel anti-infective agents for serious bacterial infections. Its primary product, Xenleta (lefamulin), is an intravenous and oral antibiotic specifically for community-acquired bacterial pneumonia (CABP). The company advances drugs from the pleuromutilin class of antibiotics, representing a differentiated therapeutic approach.
Founded in 2006, Rodger Novak was a key figure in Nabriva's establishment. The foundational insight arose from the critical need for new solutions to combat escalating antimicrobial resistance. This involved exploring novel antibiotic classes that target bacterial growth via distinct pathways, addressing unmet medical needs in infectious diseases.
Nabriva's products are utilized by healthcare providers to treat patients with serious bacterial infections, offering crucial therapeutic options. The company's vision is to address the global health challenge of antimicrobial resistance by discovering, developing, and commercializing innovative anti-infective solutions, thereby improving patient outcomes against increasingly resistant pathogens.
Nabriva Therapeutics has raised $142.1M across 2 funding rounds.
Nabriva Therapeutics has raised $142.1M in total across 2 funding rounds.
Nabriva Therapeutics has raised $142.1M in total across 2 funding rounds.
Nabriva Therapeutics's investors include OrbiMed, Chen Yu, Novartis Venture Fund, Omega Funds, Boxer Capital, EcoR1 Capital, Global Life Science Ventures, HBM-MedFocus, Novartis, Phase4 Partners, GLS Ventures, HBM Partners.
The premise of your query is incorrect: Nabriva Therapeutics is not a technology company—it is a biopharmaceutical company[1][2][3].
Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing novel anti-infective agents to treat serious infections[1][2]. The company serves patients and healthcare systems requiring advanced antibiotics for conditions ranging from acute bacterial skin infections to hospital-acquired pneumonia. Nabriva addresses a critical healthcare problem: the rising threat of antibiotic-resistant infections, which demands new therapeutic options beyond existing treatment classes.
The company is headquartered in Dublin, Ireland, and operates with approximately 73 employees[2]. Its revenue stands at $34.4 million[2], reflecting its stage as a clinical and commercial-stage biopharmaceutical enterprise rather than a mature technology firm.
Nabriva's pipeline includes several differentiated products:
These products represent novel chemical classes and mechanisms of action, positioning Nabriva within the specialized field of anti-infective innovation.
Nabriva operates within the critical antimicrobial resistance (AMR) crisis. As bacterial pathogens develop resistance to conventional antibiotics, companies developing novel anti-infective agents play an essential role in maintaining treatment options for serious infections. The company's focus on pleuromutilin and oxazolidinone classes addresses unmet needs in hospital and community settings.
Nabriva's trajectory reflects the challenges and opportunities in specialty biopharmaceuticals. The company's ability to advance XENLETA through multiple clinical trials and maintain a commercial presence with SIVEXTRO demonstrates execution capability. However, as a smaller biopharmaceutical firm with limited revenue, Nabriva's future depends on successful clinical development, regulatory approvals, and partnerships to expand market reach for its anti-infective portfolio.
Nabriva Therapeutics has raised $142.1M across 2 funding rounds. Most recently, it raised $120.0M Series B in April 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2015 | $120.0M Series B | OrbiMed, Chen Yu | Novartis Venture Fund, Omega Funds, Boxer Capital, EcoR1 Capital, Global Life Science Ventures, HBM-MedFocus, Novartis, Phase4 Partners |
| Oct 28, 2009 | $22.1M Other Equity | GLS Ventures, HBM Partners, Nomura Phase4 Ventures Limited, Novartis |